DMRA

Damora Therapeutics is a preclinical-stage biotechnology company focused on developing product candidates, with DMR-001 being its primary program. The excerpt does not provide sufficient detail about the company's specific therapeutic areas or drug modalities. Damora recently acquired Pre-Acquisition Damora in November 2025 and relies on third-party collaborations, including one with Paragon, to advance its programs toward clinical development.

Pipeline

Catalyst Calendar